ALOPECIA (HAIR LOSS) TREATMENT MARKET FORECAST 2019-2027
• The global alopecia treatment market is expected to proliferate at 5.51% CAGR during the forecasting years of 2019-2027. • The alopecia (hair loss) treatment market in North America is expected to hold the largest share by 2027 and is expected to grow at a CAGR of xx% during the forecasting years.
• Growing disposable income coupled with the rising penetration of celebrity culture among the mass and the increased emphasis on visual appearance is contributing to the alopecia treatment market growth. • Increasing cases of chronic diseases such as Polycystic Ovary Syndrome (PCOS), Rheumatoid Arthritis and cancer causes a higher rate of occurrence of alopecia which is further profiting the said market. • The high economic development in the developing countries and the initiatives of organizations, such as National Alopecia Areata Foundation, American Hair Loss Association, etc. across several corners of the world are helping to spread awareness about alopecia and the available treatments are resulting in growth in healthcare expenditure specifically for the market.
“The global alopecia treatment market is expected to proliferate at 5.51% CAGR during the forecasting years of 2019-2027.�
The alopecia treatment market of North America is expected to proliferate at a growth rate of 4.80% CAGR during the forecasting years of 2019-2027.
The European alopecia treatment market is expected to grow at a CAGR of 4.52% during the forecasting years 2019-2027.
The Asia Pacific alopecia treatment market is expected to grow at a CAGR of 7.38% during the forecasting years of 2019-2027.
Concert Pharmaceuticals Inc., Histogen Inc., Dr Reddy’s Laboratories Ltd., Merck & Co., Inc., Alès Groupe, Alpecin, Sun Pharmaceutical Industries Ltd., Vitabiotics Ltd., Aclaris Therapeutics Inc., Johnson and Johnson, GlaxoSmithKline, Daiichi Sankyo, Inc., Lifes2good, Cipla and HCell Inc. are some of the companies operating in the global market.